GLOBAL Impact of COVID-19 Pandemic
on Clinical Trials
Wondering how the COVID-19 pandemic has impacted clinical trials worldwide?
Explore the effects conveniently with our user-friendly data visualizer.
Clinical trials are critical for advancing medical research, but the pandemic has posed significant challenges. From patient recruitment to trial timelines, the COVID-19 pandemic has had a profound impact on clinical research.
Our interactive data visualizer allows you to easily compare the number of non-COVID-19 clinical trials to COVID-19 clinical trials from 2015 to 2022.
You can filter the data by country, trial phase, trial status, and other parameters to see how the numbers change over time.
- There has been a significant shift in the distribution of clinical trials in 2020 toward regions heavily affected by the COVID-19 pandemic.
- There has been a decrease in the number of non-COVID-19 clinical trials being conducted in regions heavily affected by the pandemic in 2020.
- There has been a significant increase in COVID-19 clinical trials being conducted globally from 2020 onwards.
- Countries that conducted most of the clinical trials also have the biggest number of COVID-related trials conducted.
To see detailed information on the selected country scroll down
- Aside from China, Australia, and Brazil, there was no significant shift in the distribution of clinical trials toward regions heavily affected by the COVID-19 pandemic in 2020.
- Indeed, there has been a decrease in the number of non-COVID-19 clinical trials being conducted in regions heavily affected by the pandemic, aside from China and Australia who experienced growth in non-COVID-19 clinical trials in 2020.
- Indeed, there has been a significant increase in COVID-19 clinical trials being conducted globally from 2020 onwards.
- Indeed, countries that conducted most of the clinical trials also have the biggest number of COVID-19-related trials conducted.
- COVID-19 has led to a greater proportion of (non-COVID-19) "active" trials with a "not yet recruiting" status in the period 2020-2022.
- COVID-19 has led to a lower proportion of (non-COVID-19) "active" trials with a "recruiting" status in the period 2020-2022.
- COVID-19 disruptions have resulted in a decrease in the proportion of (non-COVID-19) clinical trials with a "completed" or "terminated" status.
- COVID-19 disruptions have resulted in a increase in the proportion of (non-COVID-19) clinical trials with a "completed" or "terminated" status in the period 2020-2022.
- Indeed, COVID-19 has led to a greater proportion of (non-COVID-19) "active" trials with a "not yet recruiting" status in the period 2020-2022.
- In fact, data suggests there has been an increase in the proportion of (non-COVID-19) "active" trials with a "recruiting" status in the period 2020-2022.
- In fact, data suggests there has been a decrease in the proportion of (non-COVID-19) trials with a "completed" and "terminated" status in the period 2020-2022.
- COVID-19 has led to a greater number of clinical trials being conducted in phase I and phase II.
- COVID-19 has led to a lower number of clinical trials being conducted in phase III and phase IV.
- COVID-19 has led to a higher proportion of clinical trials with expedited approval and emergency use designations.
- There is no sufficient data evidence that suggest COVID-19 has led to a greater number of clinical trials being conducted in phase I and phase II.
- Indeed, COVID-19 has led to a lower number of clinical trials being conducted in phase III and phase IV.
- The COVID-19 pandemic has resulted in a greater emphasis on drug therapies and vaccines as the primary intervention type in clinical trials.
- Because of the increase in remote monitoring, the number of device interventions should increase.
- Indeed, The COVID-19 pandemic has resulted in a greater emphasis on drug therapies and vaccines as the primary intervention type in clinical trials.
- Indeed, the number of device interventions increased.
- The COVID-19 pandemic has resulted in a significant increase in the number of clinical trials focused on infectious and respiratory diseases.
- Indeed, the COVID-19 pandemic has resulted in a significant increase in the number of clinical trials focused on infectious and respiratory diseases.